TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. - Wikidata - awgldk - TriplyDB

TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.

TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.

http://www.wikidata.org/entity/Q33432504

about

The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma A20 inhibits LUBAC-mediated NF-κB activation by binding linear polyubiquitin chains via its zinc finger 7 The A20 deubiquitinase activity negatively regulates LMP1 activation of IRF7 The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling Unexpected functions of nuclear factor-κB during germinal center B-cell development: implications for lymphomagenesis Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-κB regulation The role of aberrant proteolysis in lymphomagenesis Oncogenically active MYD88 mutations in human lymphoma An enhancer element harboring variants associated with systemic lupus erythematosus engages the TNFAIP3 promoter to influence A20 expression A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.Targeting A20 decreases glioma stem cell survival and tumor growth.NF-κB Pathway in Autoinflammatory Diseases: Dysregulation of Protein Modifications by Ubiquitin Defines a New Category of Autoinflammatory Diseases.Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type Signaling to NF-kappaB: regulation by ubiquitination.Pathobiology of hodgkin lymphoma.Molecular karyotypes of Hodgkin and Reed-Sternberg cells at disease onset reveal distinct copy number alterations in chemosensitive versus refractory Hodgkin lymphoma Oncogenic activation of NF-kappaB.Molecular control of steady-state dendritic cell maturation and immune homeostasis.Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.How do viruses trick B cells into becoming lymphomas?The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity.A critical role for the NFkB pathway in multiple myeloma.A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.Germinal center B cell maintenance and differentiation are controlled by distinct NF-κB transcription factor subunits.Hodgkin's Lymphomas: A Tumor Recognized by Its Microenvironment.Primary mediastinal large B-cell lymphoma.Clinical, molecular, and environmental risk factors for hodgkin lymphoma.Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets.EBV in Hodgkin Lymphoma.A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.The molecular pathogenesis of Hodgkin lymphoma.Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease.Hodgkin lymphoma.TNFAIP3 gene polymorphisms in a Chinese Han population with Vogt-Koyanagi-Harada syndrome.Protein ubiquitination in lymphoid malignancies.Extranodal NK/T-cell lymphoma: toward the identification of clinical molecular targets

P2860

Q24294856-238392A3-9CCB-4A1B-ABC7-812AEAFC93F1 Q24300148-8A14488C-4082-4A88-A1C4-F9E52A16747A Q24306662-E6B3F422-8B38-44F3-ABFB-C3189FC38416 Q24629152-A11033EE-C5DD-48F5-BFBB-2289D3C48735 Q26822486-841F9906-1282-46F5-BE73-2C94310439CA Q27314737-838967EB-8C0C-459A-9B41-4697F843550C Q27674024-D55FB7FC-0E3F-4688-A228-E3BA6E6AF182 Q28084404-178936D0-59E7-4403-809B-BB22E1334777 Q28301648-C576C5B3-4091-4B86-BA2D-359B5B70F56B Q28536781-0B8785B5-189F-4908-9958-DC25064F9C6A Q28943455-768FF1BB-95AA-4724-97D7-CC429A301FF0 Q30248284-F3C8B636-B7FC-44A6-9391-BDED0119D6DB Q33534629-BE051CA5-498F-4897-957A-060753D574E5 Q33576114-0C37C95E-EE1B-49E4-99C9-9A26E8B868C6 Q33677463-9FBDACB8-CF1C-4772-907B-41D3D128F250 Q33693806-542FE0ED-314D-4484-AA09-7247C9259658 Q33778402-5175EE14-AC55-4D36-8062-2E00A29E85D3 Q33840504-631EDDCD-02AA-441D-9DA5-0DA63E6405D6 Q33849388-D14C887F-DC4B-4FF0-94CF-5A437DE5340B Q33882051-FE83FC93-E670-49F2-81E0-D5BA1F67CED5 Q33889168-7AF55814-E8E7-4AC7-B8D7-0853E728139B Q34020096-738323BD-63B4-450C-A98D-213CA8676969 Q34097297-08FA268B-D752-4AE0-B71D-3F994E100885 Q34165181-A37FE121-964E-488B-AE00-5C02C83D863C Q34220013-7F79DBAA-A2CC-489F-8601-2100BBB0B1F5 Q34230576-316C7517-4444-4223-BCF7-C442A0EC8A1A Q34235750-E4B868A7-1F0F-4677-9DEF-F68CCF4CD2EE Q34266819-4BA23A61-1645-418F-9D98-56298BDD5B25 Q34362539-B9325AA8-4264-4A8A-8075-18AE6718B1C3 Q34435074-86849EDB-ED34-4CFE-88AF-DDE06ED64CD1 Q34492636-36A32763-5BC8-49D6-A556-17A6F65E42DD Q34503492-ADAF1EE3-5270-4E69-8FEB-3C12C0746776 Q34549468-043EEBE2-5DAC-4A19-A705-5BAE9616FBC9 Q34590254-776ACBDE-0760-4888-9573-67B07D659861 Q34626576-52030DA6-1909-44D8-AA55-C33003F8F8CC Q34631192-AEFAE90F-7E5F-4BA7-94E4-7A20B57CFD47 Q34643277-2AC3A4BA-7F7B-4C7D-BEAD-3A2908F9D6FF Q34651381-E9A1EC49-B111-409B-962F-D457779C5DD6 Q34722684-1420B004-F72E-4E76-9529-F013368A3F13 Q34898306-E80109D3-0988-4699-B0C7-FF876AD328F7

P2860

TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.

http://www.wikidata.org/entity/Q33432504

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

TNFAIP3 (A20) is a tumor suppr ...... y mediastinal B cell lymphoma.

@ast

TNFAIP3 (A20) is a tumor suppr ...... y mediastinal B cell lymphoma.

@en

type

label

TNFAIP3 (A20) is a tumor suppr ...... y mediastinal B cell lymphoma.

@ast

TNFAIP3 (A20) is a tumor suppr ...... y mediastinal B cell lymphoma.

@en

prefLabel

TNFAIP3 (A20) is a tumor suppr ...... y mediastinal B cell lymphoma.

@ast

TNFAIP3 (A20) is a tumor suppr ...... y mediastinal B cell lymphoma.

@en

P1433

Q33432504-A61C0F19-1867-48AE-9AE3-A2C5C1F9543A

P1476

Q33432504-55163C41-DD91-4DF9-9A37-277459161E27

P2093

Q33432504-01B870BA-077F-4425-B0CB-93211A4A6165

Q33432504-0C665AC2-3986-4208-9F3D-2B353C898209

Q33432504-1CB3DA35-A338-49CE-B98E-A96D58C8075A

Q33432504-230CB760-B798-4520-8DAF-30B29F5A197B

Q33432504-31AB2F1C-B5BF-4663-AD5E-325DFF790476

Q33432504-4245697F-5E2A-417D-A4BF-4041102C8C15

Q33432504-A1C092D5-BAD9-4135-ABD1-167B5B5767C6

P2860

Q33432504-0190A0E7-D398-498B-BA49-42B548745B1A

Q33432504-0585725A-0C32-43E3-96EE-BE6D1266B3DF

Q33432504-0E771727-8D5D-447F-88C8-00A5F102A5A7

Q33432504-0EFA1942-86F5-47C3-B2B9-8A1C730E94BD

Q33432504-182434F1-B5CF-413E-A6B8-0B48C2AB690E

Q33432504-19A437E5-6FFA-47F3-94CB-692E9EC3EE57

Q33432504-1DA8C6F8-E9F6-49AF-8AEC-DF292A78B67B

Q33432504-28BC2D35-66DB-42D2-AC1D-AB1F323E5180

Q33432504-2C0CE29A-E74B-40D8-AB6E-165A84774B64

Q33432504-2CD02B34-40F2-4274-B678-7F838040A596

P304

Q33432504-C71C8E55-8143-456B-B130-3AC293FBE3DE

P31

Q33432504-5BEBF473-42F9-4234-8955-41E9128BA9CE

P356

Q33432504-019CF50A-F20E-42B5-9705-998DAF315F16

P407

Q33432504-B3F3CDAC-1910-4FCF-A62F-B79DB14C0271

P433

Q33432504-4CF8C867-0D9D-426C-9455-E40A9540B6C0

P478

Q33432504-DA475B94-3DEC-4AD9-8053-1459FBAA3096

P50

Q33432504-13DEAAF1-5954-4DF0-953F-AD30AE05E271

Q33432504-79BA066E-3C60-4AC4-B132-3DAAC945C843

Q33432504-99442A4C-DF6F-492D-952D-D91342A9CEBD

Q33432504-ACA57521-395C-457A-B173-CF8F0D381306

Q33432504-C8C98BB0-50D1-4B65-A80E-C9E41419484E

Q33432504-D5407222-26B0-409E-A294-231D5B093789

P577

Q33432504-BCA53026-1920-4528-A9A9-BB2222A3B33F

P5875

Q33432504-D6AF88C5-DDF7-4BD1-BD41-CC39A66AC779

P698

Q33432504-29B4DBBA-D38A-4884-A648-7E4A95F9BD46

P932

Q33432504-86575009-145B-4D15-B890-B6C82CADAEE7

P356

P1433

Journal of Experimental Medicine

P1476

TNFAIP3 (A20) is a tumor suppr ...... y mediastinal B cell lymphoma.

@en

P2093

Gunhild Mechtersheimer

http://www.w3.org/2001/XMLSchema#string

Jens Stanelle

http://www.w3.org/2001/XMLSchema#string

Roland Schmitz

http://www.w3.org/2001/XMLSchema#string

Stefan Gesk

http://www.w3.org/2001/XMLSchema#string

Sylvia Hartmann

http://www.w3.org/2001/XMLSchema#string

Verena Bohle

http://www.w3.org/2001/XMLSchema#string

Wolfram Klapper

http://www.w3.org/2001/XMLSchema#string

P2860

De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling

T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20

Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli

The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation

Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice

Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity

The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals

Shared principles in NF-kappaB signaling

The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses

Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO

P304

981-989

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20090528

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

206

http://www.w3.org/2001/XMLSchema#string

P50

Martin-Leo Hansmann

José I Martín-Subero

P577

2009-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24311496

http://www.w3.org/2001/XMLSchema#string

P698

19380639

http://www.w3.org/2001/XMLSchema#string

P932

2715030

http://www.w3.org/2001/XMLSchema#string